Advice
following a full submission
edoxaban (Lixiana®) is accepted for use within NHS Scotland.
Indication under review: for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).
One phase III study showed non-inferiority of edoxaban versus a vitamin K antagonist for the prevention of stroke and systemic embolism in adult patients with NVAF and a CHADS2 score of ≥2. It was also associated with a significant reduction in risk of major bleeding.
Download detailed advice218KB (PDF)
Medicine details
- Medicine name:
- edoxaban (Lixiana)
- SMC ID:
- 1095/15
- Indication:
- For prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 November 2015